The Kura Oncology, Inc. (KURA) Downgraded to “Hold” at Zacks Investment Research

The Kura Oncology, Inc. (KURA) Downgraded to “Hold” at Zacks Investment Research

Kura Oncology, Inc. (NASDAQ:KURA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “Kura Oncology, Inc. is a biopharmaceutical company. The company is involved in the discovery and development of therapeutics for the treatment of tumors and blood cancers. Its product pipeline includes small molecule drug candidates which are in different clinical trial consists of Tipifarnib-HRAS, Tipifarnib-PTCL, ERK inhibitor program and Menin MLL inhibitor program. Kura Oncology, Inc. is headquartered in La Jolla, California. “

A number of other research analysts also recently issued reports on the stock. Oppenheimer Holdings, Inc. set a $16.00 target price on shares of Kura Oncology and gave the company a “buy” rating in a research report on Tuesday. Leerink Swann restated an “outperform” rating and set a $15.00 target price on shares of Kura Oncology in a research report on Thursday, October 13th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $14.80.

Kura Oncology (NASDAQ:KURA) opened at 6.05 on Thursday. The company’s market cap is $115.22 million. Kura Oncology has a 12-month low of $2.50 and a 12-month high of $7.24. The firm’s 50 day moving average is $5.84 and its 200 day moving average is $5.31.

Kura Oncology (NASDAQ:KURA) last posted its quarterly earnings data on Monday, November 7th. The company reported ($0.37) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.03. Equities research analysts anticipate that Kura Oncology will post ($1.49) EPS for the current fiscal year.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Minerva Advisors LLC purchased a new position in Kura Oncology during the second quarter worth $977,000. Partner Investment Management L.P. boosted its position in Kura Oncology by 2.7% in the third quarter. Partner Investment Management L.P. now owns 23,646 shares of the company’s stock worth $148,000 after buying an additional 623 shares during the last quarter. Finally, Pillar Pacific Capital Management LLC purchased a new position in Kura Oncology during the third quarter worth $191,000. 45.64% of the stock is owned by institutional investors.

About Kura Oncology

Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.

Get a free copy of the Zacks research report on Kura Oncology (KURA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Related posts

Leave a Comment